<DOC>
	<DOC>NCT01986101</DOC>
	<brief_summary>The study evaluates the efficacy and safety of SM-13496 compared with placebo in patients with Bipolar I Depression.</brief_summary>
	<brief_title>A Phase III Study of SM-13496 in Patients With Bipolar I Depression.</brief_title>
	<detailed_description>The primary objective is to compare the efficacy of SM-13496 (20-60 or 80-120 mg/day) monotherapy with that of placebo in patients with depressive symptoms associated with bipolar I disorder by assessing the change from baseline in the MADRS total score at Week 6.</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Lurasidone Hydrochloride</mesh_term>
	<criteria>Patients who were fully informed of and understand the objectives, procedures, and possible benefits and risks of the study and who provided written voluntary consent to participate in the study. Outpatients aged 18 through 74 years at the time of consent Patients meets DSMIVTR criteria for bipolar I disorder, most recent episode depressed (â‰¥ 4 weeks and less than 12 months) without psychotic features. Patients with imminent risk of suicide or injury to self, others, or property. Patients who had been hospitalized because of a manic or mixed episode within 60 days prior to screening. Patients who are otherwise considered ineligible for the study by the investigator.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>